KEY ACCOUNT MANAGER ONCOLOGY
Pubblicato il 03-10-2026 - Pharma Point in Campania
Our client is an international biotechnology company focused on the development of innovative oncology therapies, currently strengthening its direct presence in the Italian market.
As part of this expansion, we are looking for an experienced Oncology Key Account Manager who will contribute to the launch and development of a highly innovative oncology portfolio, with a particular focus on solid tumors and gynecologic oncology.
Territory
Central-Southern Italy
The Role
The Oncology Key Account Manager will be responsible for developing the Company’s presence across the assigned territory, building strong relationships with hospitals, cancer centers, academic institutions and key oncology stakeholders.
The role combines strategic account management, scientific engagement, commercial excellence and regional/local market access, supporting product adoption and optimal patient access.
Key Responsibilities
- Develop and execute the territory business plan, identifying priorities, opportunities and key accounts.
- Build strong relationships with oncologists, KOLs,
multidisciplinary teams and relevant decision-makers.
- Drive product adoption and support the launch of innovative oncology treatments.
- Develop a deep understanding of the territory, competitive landscape and patient pathways.
- Work cross-functionally with Medical Affairs, Marketing and Market Access.
- Identify and address barriers to patient access at regional and hospital level.
- Engage with hospital pharmacists, payers, procurement teams and stakeholders involved in local access decisions.
- Support product inclusion in hospital formularies, therapeutic pathways and local protocols.
- Manage territory activities and resources in line with company policies and applicable regulations.
Requirements
- Minimum 5 years of pharmaceutical sales experience, including at least 3 years in oncology.
- Strong experience within the solid tumor market; experience in gynecologic oncology and/or ADCs will be considered a